These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10415076)

  • 1. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
    Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Sznol M; Schwarz SL; Spiess PJ; Wunderlich JR; Seipp CA; Einhorn JH; Rogers-Freezer L; White DE
    J Immunol; 1999 Aug; 163(3):1690-5. PubMed ID: 10415076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
    Roberts JD; Niedzwiecki D; Carson WE; Chapman PB; Gajewski TF; Ernstoff MS; Hodi FS; Shea C; Leong SP; Johnson J; Zhang D; Houghton A; Haluska FG;
    J Immunother; 2006; 29(1):95-101. PubMed ID: 16365605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
    Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
    J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
    Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
    J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine.
    Stewart JH; Rosenberg SA
    J Immunother; 2000; 23(4):401-4. PubMed ID: 10916748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of TCR use in response to repeated epitope-specific immunization.
    Monsurrò V; Nielsen MB; Perez-Diez A; Dudley ME; Wang E; Rosenberg SA; Marincola FM
    J Immunol; 2001 May; 166(9):5817-25. PubMed ID: 11313426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
    Lee KH; Wang E; Nielsen MB; Wunderlich J; Migueles S; Connors M; Steinberg SM; Rosenberg SA; Marincola FM
    J Immunol; 1999 Dec; 163(11):6292-300. PubMed ID: 10570323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
    Salgaller ML; Marincola FM; Cormier JN; Rosenberg SA
    Cancer Res; 1996 Oct; 56(20):4749-57. PubMed ID: 8840994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
    Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
    Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
    Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
    Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
    J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
    Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL
    J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
    Chianese-Bullock KA; Woodson EM; Tao H; Boerner SA; Smolkin M; Grosh WW; Neese PY; Merrill P; Petroni GR; Slingluff CL
    J Immunother; 2005; 28(4):412-9. PubMed ID: 16000961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.